Pyxis Oncology enters amended license deal with Pfizer for ADC platform; pays $8M cash + $10M in stock

Pyxis Oncology, Inc.

Pyxis pays Pfizer $8M cash and issues ~2.23M shares ($5M) on closing, plus $5M in shares 180 days later.
Pfizer grants exclusive worldwide rights to FACT platform for ADCs targeting PYX-201 and PYX-203.
Shares are unregistered, relying on Section 4(a)(2) exemption from the Securities Act.
Post-issuance, Pyxis had ~35.1M shares outstanding as of October 6, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.